<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5C8397A0-E026-493D-91AC-6C8DD2BCAF75"><gtr:id>5C8397A0-E026-493D-91AC-6C8DD2BCAF75</gtr:id><gtr:firstName>Daisy</gtr:firstName><gtr:otherNames>Helen</gtr:otherNames><gtr:surname>Luff</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F000L0799"><gtr:id>8E62C676-AF18-45CC-9B62-E53D07766AD7</gtr:id><gtr:title>Rules of engagement: differential activation of the P13k isoforms p110a and p110d in lymphocytes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/000L0799</gtr:grantReference><gtr:abstractText>The PI3Ks are a family of lipid kinases which are essential for mammalian development and function. Immune cells can express up to 8 different isoforms of PI3K divided into three classes. The class I PI3Ks p110a, p110&amp;szlig;, p110d and p110? can each be recruited to different receptors in B cells and T cells. Our laboratory has defined distinct roles for p110a and p110d during lymphocyte activation and development. P110a is essential for embryonic development and is the most frequently mutated kinase in human cancer, yet surprisingly does not seem to play a significant role in mature lymphocytes. By contrast, p110d is dispensable for normal development, has never been found mutated in cancers, but is essential for normal lymphocyte activation. Using newly developed genetically modified mice with inducible and tissue-specific expression of p110 subunits, you will test the hypothesis that oncogenic mutants of p110a can substitute for the loss of p110d (which at the sequence level mimics oncogenically mutated p110a). In parallel, protein complexes containing p110a or p110d will be isolated from lymphocytes and resolved by biochemical analysis and mass spectroscopy to discover protein partners that are common or unique to these two kinases. These experiments will shed light on the evolutionary pressure that led to the selection of a PI3K isoform used specifically by cells of the immune system and how this is mimicked during the micro-evolutionary selection of mutant clones during cancer progression.</gtr:abstractText><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-10-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>87034</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/000L0799</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>